CN108697711A - 伊马替尼在治疗中风中的用途 - Google Patents

伊马替尼在治疗中风中的用途 Download PDF

Info

Publication number
CN108697711A
CN108697711A CN201780013732.6A CN201780013732A CN108697711A CN 108697711 A CN108697711 A CN 108697711A CN 201780013732 A CN201780013732 A CN 201780013732A CN 108697711 A CN108697711 A CN 108697711A
Authority
CN
China
Prior art keywords
imatinib
administered
patient
days
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780013732.6A
Other languages
English (en)
Chinese (zh)
Inventor
乌尔夫·埃里克森
尼尔斯·贡纳尔·瓦尔格伦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brain Consultant Nils Gunnar Wahlgren AB
Hamra Invest AB
Original Assignee
Brain Consultant Nils Gunnar Wahlgren AB
Hamra Invest AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brain Consultant Nils Gunnar Wahlgren AB, Hamra Invest AB filed Critical Brain Consultant Nils Gunnar Wahlgren AB
Priority to CN202411509669.3A priority Critical patent/CN119523986A/zh
Publication of CN108697711A publication Critical patent/CN108697711A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201780013732.6A 2016-02-29 2017-02-27 伊马替尼在治疗中风中的用途 Pending CN108697711A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202411509669.3A CN119523986A (zh) 2016-02-29 2017-02-27 伊马替尼在治疗中风中的用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE1650260A SE539450C2 (en) 2016-02-29 2016-02-29 Imatinib for use in the treatment of stroke
SE1650260-1 2016-02-29
PCT/SE2017/050183 WO2017151043A1 (en) 2016-02-29 2017-02-27 Imatinib for use in the treatment of stroke

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202411509669.3A Division CN119523986A (zh) 2016-02-29 2017-02-27 伊马替尼在治疗中风中的用途

Publications (1)

Publication Number Publication Date
CN108697711A true CN108697711A (zh) 2018-10-23

Family

ID=59744327

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201780013732.6A Pending CN108697711A (zh) 2016-02-29 2017-02-27 伊马替尼在治疗中风中的用途
CN202411509669.3A Pending CN119523986A (zh) 2016-02-29 2017-02-27 伊马替尼在治疗中风中的用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202411509669.3A Pending CN119523986A (zh) 2016-02-29 2017-02-27 伊马替尼在治疗中风中的用途

Country Status (17)

Country Link
US (2) US10953010B2 (https=)
EP (1) EP3423060B1 (https=)
JP (1) JP6914957B2 (https=)
CN (2) CN108697711A (https=)
AU (1) AU2017227515B2 (https=)
DK (1) DK3423060T3 (https=)
ES (1) ES2895432T3 (https=)
HR (1) HRP20211621T1 (https=)
HU (1) HUE056798T2 (https=)
LT (1) LT3423060T (https=)
PL (1) PL3423060T3 (https=)
PT (1) PT3423060T (https=)
RS (1) RS62465B1 (https=)
RU (1) RU2739382C1 (https=)
SE (1) SE539450C2 (https=)
SI (1) SI3423060T1 (https=)
WO (1) WO2017151043A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114306342A (zh) * 2020-09-30 2022-04-12 江苏先声药业有限公司 一种注射用伊马替尼盐的药物组合物及其制备方法

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10617756B2 (en) * 2017-01-05 2020-04-14 Shimojani, LLC Drug regimen for treatment of cerebral ischemia
CN118524852A (zh) * 2021-11-09 2024-08-20 真和制药有限公司 治疗或抑制心血管疾病的方法
EP4311539A1 (en) 2022-07-29 2024-01-31 Artorange Ltd. Imatinib formulation for parenteral administration
US20250000934A1 (en) 2023-06-28 2025-01-02 Pharmazz, Inc. Lyophilized sovateltide-based injectable formulation and method for preparation thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007124308A2 (en) * 2006-04-17 2007-11-01 Ludwig Institute For Cancer Research Methods and compositions for modulation of blood-neural barrier

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY148074A (en) * 2005-05-10 2013-02-28 Novartis Ag Pharmaceutical compositions comprising imatinib and a release retardant
US7977348B2 (en) * 2006-04-27 2011-07-12 Sicor Inc. Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form α
WO2008057291A2 (en) * 2006-10-26 2008-05-15 Sicor Inc. Crystalline and amorphous imatinib base, imatinib mesylate- and processes for preparation thereof
US20100136094A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
TR201911199T4 (tr) * 2009-03-27 2019-08-21 Moleac Pte Ltd Hücre büyümesini arttırmak için tedavi.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007124308A2 (en) * 2006-04-17 2007-11-01 Ludwig Institute For Cancer Research Methods and compositions for modulation of blood-neural barrier

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
E.J.SU等: "Activation of PDGF-CC by Tissue Plasminogen Activator ImpairsBlood Brain Barrier Integrity During Ischemic Stroke", 《NAT MED》 *
ZAMIR MERALI等: "Longitudinal Assessment of Imatinib’s Effect on the Blood–Brain Barrier After Ischemia/Reperfusion Injurywith Permeability MRI", 《TRANSL. STROKE RES》 *
马娟: "《冠心病二级预防—从指南到临床》", 31 December 2015, 云南科技出版社 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114306342A (zh) * 2020-09-30 2022-04-12 江苏先声药业有限公司 一种注射用伊马替尼盐的药物组合物及其制备方法
CN114306342B (zh) * 2020-09-30 2024-06-28 江苏先声药业有限公司 一种注射用伊马替尼盐的药物组合物及其制备方法

Also Published As

Publication number Publication date
SE539450C2 (en) 2017-09-26
DK3423060T3 (da) 2021-10-25
US20210236488A1 (en) 2021-08-05
EP3423060A1 (en) 2019-01-09
JP2019507165A (ja) 2019-03-14
WO2017151043A1 (en) 2017-09-08
PT3423060T (pt) 2021-10-20
PL3423060T3 (pl) 2022-01-10
ES2895432T3 (es) 2022-02-21
HUE056798T2 (hu) 2022-03-28
EP3423060B1 (en) 2021-07-21
EP3423060A4 (en) 2020-01-01
RS62465B1 (sr) 2021-11-30
US10953010B2 (en) 2021-03-23
AU2017227515B2 (en) 2022-03-24
RU2739382C1 (ru) 2020-12-23
JP6914957B2 (ja) 2021-08-04
US20190030030A1 (en) 2019-01-31
SE1650260A1 (en) 2017-08-30
SI3423060T1 (sl) 2021-11-30
LT3423060T (lt) 2021-11-10
HRP20211621T1 (hr) 2022-02-04
AU2017227515A1 (en) 2018-08-30
CN119523986A (zh) 2025-02-28

Similar Documents

Publication Publication Date Title
JP7810762B2 (ja) Ｃｎｓ浮腫に関連する損傷または状態を処置する方法
US20210236488A1 (en) Imatinib for use in the treatment of stroke
US20220152059A1 (en) Methods and compositions for treating various disorders
JP6208235B2 (ja) 多発性硬化症治療のためのビオチンの使用
Diringer et al. Aneurysmal subarachnoid hemorrhage: strategies for preventing vasospasm in the intensive care unit
US20110319384A1 (en) Pharmaceutical Compositions
EA034864B1 (ru) Способ лечения эозинофильной астмы со степенью тяжести от умеренной до тяжёлой
KR20240162094A (ko) 미르다메티닙 치료
JP2023539567A (ja) 神経活性ステロイドを含有する医薬組成物及びその使用
JP2022173299A (ja) 中枢神経系（ｃｎｓ）がんを治療するためのプロテアソーム阻害剤の利用
JP2024523559A (ja) アルドステロン合成酵素阻害剤を使用する方法
JP2024539476A5 (https=)
Choulis Miscellaneous drugs, materials, medical devices and techniques
Giaquinto Side effects of drugs that affect blood coagulation, fibrinolysis and hemostasis
Bello et al. Central nervous system stimulants and drugs that suppress appetite
RU2821032C1 (ru) Способы лечения заболеваний, связанных с рецептором s1p1
US20240100069A1 (en) Methods and Compositions for Treating Amyotrophic Lateral Sclerosis
Steglatro New Drug Approvals
TW202342049A (zh) 治療患有腦損傷的患者的方法以及增加患有腦損傷的患者的擴展版格拉斯哥結局量表的值的方法
WO2026092748A1 (zh) 雄性激素合成抑制剂与parp抑制剂联合用于治疗前列腺癌
WO2016047662A1 (ja) 脳卒中の治療剤
KR20250114057A (ko) 맥관 기형용 의약 조성물 및 맥관 기형의 치료 방법
Song et al. Hemoptysis due to aspirin treatment alternative to warfarin therapy in a patient with atrial fibrillation
CN110840869A (zh) 二甲双胍在子宫内膜异位症药物中的应用
Sarcoma NEW DRUG APPROVALS

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20181023

RJ01 Rejection of invention patent application after publication